GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » E10

BPTH (Bio-Path Holdings) E10 : $-190.21 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Bio-Path Holdings's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.700. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-190.21 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 3.20% per year. During the past 5 years, the average E10 Growth Rate was 3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Bio-Path Holdings was 3.20% per year. The lowest was -0.40% per year. And the median was 2.30% per year.

As of today (2024-12-12), Bio-Path Holdings's current stock price is $0.7005. Bio-Path Holdings's E10 for the quarter that ended in Sep. 2024 was $-190.21. Bio-Path Holdings's Shiller PE Ratio of today is .


Bio-Path Holdings E10 Historical Data

The historical data trend for Bio-Path Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings E10 Chart

Bio-Path Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -230.91 -220.29 -218.79 -215.45 -199.88

Bio-Path Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -205.41 -199.88 -198.72 -194.74 -190.21

Competitive Comparison of Bio-Path Holdings's E10

For the Biotechnology subindustry, Bio-Path Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Shiller PE Ratio falls into.



Bio-Path Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Path Holdings's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.7/133.0289*133.0289
=-0.700

Current CPI (Sep. 2024) = 133.0289.

Bio-Path Holdings Quarterly Data

per share eps CPI Adj_EPS
201412 -80.000 99.070 -107.422
201503 -80.000 99.621 -106.828
201506 -40.000 100.684 -52.850
201509 -80.000 100.392 -106.008
201512 -80.000 99.792 -106.645
201603 -80.000 100.470 -105.925
201606 -80.000 101.688 -104.656
201609 -80.000 101.861 -104.479
201612 -52.000 101.863 -67.910
201703 -16.000 102.862 -20.692
201706 -124.000 103.349 -159.610
201709 -100.000 104.136 -127.746
201712 -79.800 104.011 -102.063
201803 -67.600 105.290 -85.410
201806 -59.200 106.317 -74.074
201809 -107.600 106.507 -134.394
201812 -53.000 105.998 -66.516
201903 -17.800 107.251 -22.078
201906 -17.400 108.070 -21.419
201909 -15.600 108.329 -19.157
201912 -14.600 108.420 -17.914
202003 -18.000 108.902 -21.988
202006 -11.000 108.767 -13.454
202009 -16.000 109.815 -19.382
202012 -11.400 109.897 -13.800
202103 -8.600 111.754 -10.237
202106 -5.200 114.631 -6.035
202109 -5.800 115.734 -6.667
202112 -11.800 117.630 -13.345
202203 -9.400 121.301 -10.309
202206 -8.400 125.017 -8.938
202209 -9.800 125.227 -10.411
202212 -10.520 125.222 -11.176
202303 -13.250 127.348 -13.841
202306 -10.640 128.729 -10.995
202309 -6.360 129.860 -6.515
202312 -4.290 129.419 -4.410
202403 -4.880 131.776 -4.926
202406 -1.160 132.554 -1.164
202409 -0.700 133.029 -0.700

Add all the adjusted EPS together and divide 10 will get our e10.


Bio-Path Holdings  (NAS:BPTH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Bio-Path Holdings E10 Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Path Holdings Business Description

Traded in Other Exchanges
N/A
Address
4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Executives
Aline Sherwood director 347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen director 1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese director 4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen director, officer: President, CEO & CFO 20651 PRINCE CREEK, KATY TX 77450
Paul Aubert director 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver director 4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller officer: COO & Secretary 17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison director 2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris director 550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read director C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison director P O BOX 150248, OGDEN UT 84415